INDEX OF SUBJECTS FOR VOLUME 35

Abscess
  infection with *E. coli* and *B. fragilis*, 18
Acquired Immune Deficiency Syndrome (AIDS)
  clinical and diagnostic analysis, 1
  with toxoplasmosis, 1
Actinomyces
  A. israelii, detection in genital tract infections, 224
  A. israelii, and intra-uterine contraceptive devices, 224
  in oral microflora, 5
Adenovirus, 219
Adenylate cyclase, of *B. pertussis*, 182
Adherence
  of *B. pertussis*, 181
  EPEC adherence factor, 270, 278
  H. influenzae, to human tissues, 129
  H. pylori, to gastric epithelial cells, 197
  S. marcescens, to bladder epithelial cells, 93
Aerobactin
  production by *E. coli* in urine, 324
Aeromonas hydrophila
  antimicrobial resistance, 264
  plasmids, 264
  virulence factors, 264
Agar bead model, 139
Agglutinogens, of *B. pertussis*, 182, 189
Amino acids
  antagonism of *S. typhimurium*, 111
  sequence of *B. pertussis* toxin, 178
  sequence in dihydrofolate reductase type VI gene, 214
Amoxycillin
  susceptibility of *H. influenzae*, 139
Ampicillin resistance, of *A. hydrophila*, 264
Anaerobes
  faecal flora in inflammatory bowel disease, 238
  gram-negative, selective medium, 294
  see also Bacteroides
Antibiotic resistance
  ampicillin, and *A. hydrophila*, 264
  carbapenem, and *X. maltophilia*, 208
  cephalosporins, and *X. maltophilia*, 208
  cephalothin, and *A. hydrophila*, 208
  expression of β-lactamases by *X. maltophilia*, 208
  gentamicin, and *A. hydrophila*, 264
  gentamicin, and *S. aureus*, 80
  kanamycin, and *A. hydrophila*, 264
  kanamycin, and *S. aureus*, 72
  methicillin, and *S. aureus*, 80
  multiresistance of *A. hydrophila*, 264
  multiresistance of *S. aureus*, 72
  neomycin, and *A. hydrophila*, 264
  neomycin, and *S. aureus*, 72
  penicillin, and *S. aureus*, 72
  penicillin, and *X. maltophilia*, 208
  prystanamycin, and *A. hydrophila*, 264
  tetracycline, and *A. hydrophila*, 264
  tetracycline, and *S. aureus*, 72
  tobramycin, and *A. hydrophila*, 264
  trimethoprim, and *S. aureus*, 72
Antibiotics and other antimicrobial substances
  amoxycillin, susceptibility of *H. influenzae*, 139
  cefixime in selective medium for *E. coli*, 107
  ciprofloxacin, interactions with coumermycin and novobiocin, 358
  ciprofloxacin, susceptibility of mycoplasmas, 89
  coumermycin, interactions with 4-quinolones, 358
  erythromycin, susceptibility of mycoplasmas, 89
  novobiocin, interactions with 4-quinolones, 358
  ofloxacin, interactions with coumermycin and novobiocin, 358
  4-quinolones, interactions with gyrase subunit B inhibitors, 358
  sulphonamide plus pyrimethamine, 1
  susceptibility testing of mycoplasmas, 89
  susceptibility testing of *X. maltophilia*, 208
  tetracycline, susceptibility testing of mycoplasmas, 89
Antibodies
  against *B. pertussis*, 176
  against hepatitis B virus, 291
  against *H. influenzae*, 139
  against interferon, 29
  against *S. typhimurium*, 53
  against *T. gondii*, 1
  see also Monoclonal antibodies
Antigens
  changes in specificities of *C. coli*, 168
  of enterotoxigenic *E. coli*, 162
  HBe, of hepatitis B virus, 291
  of *H. influenzae*, 139
  polypeptide, of *B. fragilis*, 118
  streptokinase, 60
  variation in *C. albicans*, 321
Antisera
  against antigens of *C. coli*, 168
  against *B. hominis* strains, 35
Aspergillus fumigatus
  characterisation of alkaline protease, 23
ATP bioluminescence, 89

Bacteroides
  B. fragilis, antigenic composition, 118
  B. fragilis, capsule, 229
  B. fragilis in inflammatory bowel disease, 238
  B. fragilis in intra-abdominal infection, 18
  B. fragilis in mixed infections with *E. coli*, 18
  B. fragilis monoclonal antibodies, 229
  B. fragilis polysaccharide expression, 229
  B. gracilis in periodontal infection, 294
  B. gracilis selective medium, 294
  B. ureolyticus (NTU) medium, 294
  B. vulgatus in inflammatory bowel disease, 238
Benzyl penicillin resistance, of *S. aureus*, 72
Bifidobacteria, in inflammatory bowel disease, 238
Biochemical typing schemes
  identification of viridans streptococci, 367
  phenotyping of *E. coli*, 270
  profiles of group G streptococci, 148
Bioluminescence assay, 89
Blastocystis hominis
  immunological analysis of strains, 35
BOOKS RECEIVED
  Alcohol, immunomodulation and AIDS (edited by D. Seminara, R. R. Watson and A. Paulowski), 191
  Bailey and Scott's diagnostic microbiology, 8th edition (Ellen Jo Baron and S. M. Finegold), 125
  Basic human immunology (edited by D. P. Stites and A. I. Terr), 309
  Chlamydial infections (edited by W. R. Bowie *et al.*), 309
  Infection (by R. G. Finch and P. Ball), 375
  Modern pathology of AIDS and other retroviral infections. Application of contemporary methods (edited by P. Racz, A. T. Haase and J. C. Gluckman), 191
  Papillomaviruses (edited by P. M. Howley and T. R. Broker), 192

Pathogenesis of wound and biomaterial-associated infections (edited by T. Wadstrom *et al.*), 191
Q fever. Volume I. The disease (edited by T. J. Marrie), 125
Recent advances in mycoplasmology (edited by G. Stanek *et al.*), 125
Skin Langerhans (dendric) cells in viral infections and AIDS (edited by Y. Becker), 256
Staphylococci (edited by Dorothy Jones, R. G. Board and M. Sussman), 309
Textbook of human virology (edited by R. B. Belshe), 309
Textbook of medical parasitology (by R. Panjarathinam), 309
Topley and Wilson's Principles of Bacteriology, Virology and Immunity, 8th edition (edited by M. T. Parker, L. Collier *et al.*), 375
Viral hepatitis: biological and clinical features, specific diagnosis and prophylaxis. 2nd edition (by F. B. Hollinger *et al.*), 126
Bordetella pertussis
adenylate cyclase, 182
adhesion, 181
agglutinogens, 182, 189
antibodies, 176
antigens, 175
aroA mutant strains, 186
central nervous system effects of vaccine, 188
diagnosis of infection, 188
filamentous haemagglutinin, 176
fimbriae, 181
immune response, 175
lipopolysaccharide endotoxins, 182
monoclonal antibodies, 176
pertussis toxin, 175
pharmacological assay of pertussis toxin, 180
recent developments in research, 174
role of iron in infection, 174
surveillance of serotypes, 189
tetanus toxoid potency, and vaccines, 187
tracheal cytotoxin, 184
vaccines, 176
Borrelia burgdorferi
detection in cerebrospinal fluid, 98
in neuroborreliosis, 98

Cadmium resistance of *S. aureus*, 72
Campylobacter coli
antigenic shifts in serotype determinants, 168
Candida albicans
monoclonal antibodies, 321
morphology index, 321
Capsule, of *B. fragilis*, 229
Carbapenem resistance, of *X. maltophilia*, 208
Carbapenemase activity, 208
Carbohydrates
antagonism of *S. typhimurium*, 111
Cats
group G streptococcal isolates, 148
Cefixime, in selective medium for *E. coli*, 107
Cell culture
isolation of *C. trachomatis*, 159
invasion of HEp-2 cells by *S. typhimurium*, 349
Cephalosporin resistance, of *X. maltophilia*, 208
Cephalosporinase, 208
Cephalothin resistance, of *A. hydrophila*, 264
Cerebrospinal fluid (CSF)
detection of *B. burgdorferi*, 98
Cervical smears, 224
Chemiluminescence, 65
Chlamydia
C. pneumoniae, diagnosis by Chlamydia Spot-IF test, 244
C. trachomatis, diagnosis by Chlamydia Spot-IF test, 244
C. trachomatis, DNA probe assay, 159
C. trachomatis in genital tract infections, 159
Ciprofloxacin
interactions with gyrase subunit B inhibitors, 358
susceptibility of mycoplasmas, 89
Clostridium difficile, toxin B, 40
Colonisation factor antigens, 162
Complement
fixation, automation of tests, 249
opsonisation, complement-dependent, 65
Computer-assisted numerical analysis, 297
Continuous flow cultures, 111
Copro-antibodies, 53
Coumermycin
interactions with 4-quinolones, 358
Crohn's disease, 238
Cytotoxicity, of *C. difficile* toxin B, 40
Cytotoxins
tracheal, of *B. pertussis*, 184

Densitometry, scanning, 297
Desferrioxamine
susceptibility of *S. epidermidis*, 45
Diabetes
S. marcescens in urinary tract infections, 93
Diarrhoea
enteropathogenic *E. coli* in children, 270
infantile, and enterotoxigenic *E. coli*, 162
Dihydrofolate reductase type VI
nucleotide sequence, 214
DNA
concentration of hepatitis B virus DNA, 291
gene amplification, 98
gyrase, subunit B inhibitors, 358
hybridisation, 80, 98, 152, 214, 291
probes, 80, 98, 152, 159, 188
polymerase chain reaction, 1, 98, 188, 284
restriction analysis, 80, 132, 168, 214, 297

Electronmicroscopy
adherence of *H. pylori*, 197
immuno-electronmicroscopy, 229
immuno-gold, 65
polysaccharide expression by *B. fragilis*, 229
scanning, 197, 338
surface proteins of coagulase-negative staphylococci, 65
test-tube brush formation by *E. yurii*, 338
transmission, 197, 338
ELISA, automated sample processor, 249
Endotoxins, of *B. pertussis*, 182
Enterochelin, production by *E. coli* in urine, 324
Enterotoxins, of *E. coli*, 162
Epidemiology
biochemical phenotyping of enteropathogenic *E. coli*, 270
ribotyping of *L. pneumophila*, 152
typing of *S. pyogenes*, 304
Erythromycin, susceptibility of mycoplasmas, 89
Escherichia coli
biochemical phenotyping, 270
contact-haemolysin production, 330
dihydrofolate reductase, 214
enteroaggregative, 278
enteroinvasive (EIEC), 330
enteropathogenic (EPEC), 270, 278
enterotoxigenic (ETEC), 162
EPEC adherence factor, 270, 278
epidemiology, 270

in infantile diarrhoea, 162
in inflammatory bowel disease, 238
in intra-abdominal infections, 18
mannose-resistant haemagglutinin, 278
in mixed infection with *B. fragilis*, 18
phagocytosis and killing, 12, 18
plasmid, 330
pre-opsonisation, 12
siderophore production, 324
sorbitol-MacConkey selective medium, 107
in urinary tract infections 324
verotoxigenic, 107
virulence factors, 270, 278, 324, 330
Eubacterium yurii subsp. *yurii*
test-tube brush formation, 338

Faecal bacteria
antagonism of *S. typhimurium*, 111
enterotoxigenic *E. coli*, 162
in inflammatory bowel disease, 238
semi-quantitative assessment technique, 238
Fibrin clot model, 18
Fimbriae
of *B. pertussis*, 181
of *H. influenzae*, 129
Flow cytometric analysis, 229
Fluorescence actin-staining test, 278
Fluorogenic substrates, and streptococci, 367
Formate-fumarate dependent bacteria, 294
Freeze-fracture technique, 338

Gardnerella vaginalis, in bacterial vaginosis, 103
Gastric epithelial cells
adherence of *H. pylori*, 197
Gastritis, of pigs
spiral bacterium in, 345
"*Gastrospirillum suis*"
in porcine gastric mucosa, 345
in porcine gastritis, 345
Gene amplification, 98
Genital tract infection
detection of *C. trachomatis*, 159
diagnosis of *A. hydrophila* infection, 224
diagnosis of bacterial vaginosis, 103
with intra-uterine contraceptive devices, 224
Gentamicin resistance
of *A. hydrophila*, 264
of *S. aureus*, 80
Glomerulonephritis, post-streptococcal, 60
Gram's stain
diagnosis of bacterial vaginosis, 103

Haemagglutinin, filamentous, of *B. pertussis*, 176
Haemagglutination, mannose-resistant, 278
Haemolytic activity
of *A. hydrophila*, 264
contact-haemolysin production by *E. coli*, 330
contact-haemolysin production by shigellae, 330
of enteropathogenic *E. coli*, 270
Haemophilus
H. influenzae, adherence to human tissues, 129
H. influenzae, fimbriae, 129
H. influenzae, histidine decarboxylase production, 363
H. influenzae, identification from sputum cultures, 49
H. influenzae, model of chronic lung infection, 139
H. influenzae, rapid enzyme tests, 49
H. parainfluenzae, histidine decarboxylase production, 363
Haemstrip, 49
Helicobacter pylori
adherence to gastric epithelial cells, 197
HEp-2 cells, invasiveness of *S. typhimurium*, 349

Hepatitis B virus
concentration of DNA, 291
HBe antigen, 291
Histamine production, 363
Histidine decarboxylase
from respiratory tract isolates, 363
Histoplasma capsulatum
killing by macrophages, 29
Hybridisation of DNA
detection of *B. burgdorferi* in CSF, 98
hepatitis B virus, 291
sequencing of dihydrofolate reductase gene, 214
typing of *L. pneumophila*, 152
typing of *S. aureus*, 80

Imipenem resistance, of *X. maltophilia*, 208
Immune response, to *B. pertussis* infection, 175
Immunisation
mice against *B. pertussis*, 176
mice against streptokinase, 60
mice against *S. typhimurium*, 53
Immunoblotting
antibodies to *H. influenzae*, 139
antigens of *B. fragilis*, 118
antigens of *C. coli*, 168
polysaccharide expression by *B. fragilis*, 229
surface proteins of coagulase-negative staphylococci, 65
urine, in *P. mirabilis* infection, 203
Immunodiffusion, of *B. hominis* strains, 35
Immunofluorescence, 219, 224, 229, 244, 321
Immunoglobulins
IgA, against *S. typhimurium*, 53
IgG, in chronic *H. influenzae* infection, 139
IgG, against coagulase-negative staphylococci, 65
P. mirabilis IgA protease, 203
Immuno-gold labelling, 65
Immunoperoxidase staining, 129
Inflammatory bowel disease
assessment of faecal flora, 238
Influenza viruses A and B, 219
Interferon, activation of macrophages, 29
Intestinal infection, by *Y. enterocolitica*, 257
Intra-abdominal infection
with *B. fragilis* and *E. coli*, 18
Intra-uterine contraceptive devices, 224
Iron
desferrioxamine, in identification of streptococci, 45
role in *A. hydrophila* infection, 264
role in *B. pertussis* infection, 174
siderophore production by *E. coli*, 324
test-tube brush formation by *E. yurii*, 338

Kanamycin resistance
of *A. hydrophila*, 264
of *S. aureus*, 72
Kemble star 700 sample processor, 249

β-Lactamases
expression by *X. maltophilia*, 208
Lactobacilli
in bacterial vaginosis, 103
in inflammatory bowel disease, 238
in oral microflora, 5
Legionella pneumophila
restriction fragment length polymorphism typing, 152
Lipo-oligosaccharide antigens, of *H. influenzae*, 139
Liposaccharide (LPS)
of *B. pertussis*, 182
changes in specificity in *C. coli*, 168
chlamydial, monoclonal antibody against, 244

Listeria spp.
rapid identification by Rosco system, 193
Lung lavage fluid, 139
Lyme disease, 98

Macrophages
interferon-activated, 29
killing of *H. capsulatum*, 29
in mixed infections of *E. coli* and *B. fragilis*, 18
Mannose-resistant haemagglutination, 278
Measles virus, 219
Media
B. ureolyticus (NTU), 294
for contact-haemolysin production, 330
in continuous flow culture, 111
nutrients, antagonism of *S. typhimurium*, 111
selective, for *B. gracilis*, 294
selective for formate-fumarate dependent bacteria, 294
selective for verotoxigenic *E. coli*, 107
Meningitis, 297
Meropenem resistance, of *X. maltophilia*, 208
Methicillin resistance, of *S. aureus*, 80
Micro-immunofluorescence, 244
Monoclonal antibodies
against *B. fragilis*, 229
against *C. albicans*, 321
against chlamydial lipopolysaccharide, 244
against coagulase-negative staphylococci, 65
against fimbriae of *H. influenzae*, 129
against nephritis strain-associated streptokinase, 60
against peritoneal macrophages, 18
against pertussis toxin, 176
Monocytes
activation by interferon, 29
phagocytosis of *S. epidermidis*, 65
Moraxella (Branhamella) catarrhalis
production of histidine decarboxylase, 363
Mouse model
diabetic, 93
intestinal infection with *Y. enterocolitica*, 257
passive immunity against *S. typhimurium*, 53
renal pathogenicity of *E. coli*, 324
S. marcescens in urinary tract infections, 93
Mycobacterium leprae
identification by polymerase chain reaction, 284
ribosomal RNA, 284
Mycoplasmas
antimicrobial sensitivity testing, 89
ATP bioluminescence, 89

Neomycin resistance
of *A. hydrophila*, 264
of *S. aureus*, 72
Neuroborreliosis, 98
Novibiocin, interactions with 4-quinolones, 358

Obituary: Brendan Moore, 123
Ofloxacin
interactions with gyrase subunit B inhibitors, 358
Opsonisation
complement-dependent, 65
of *E. coli*, 12
of *S. epidermidis*, 65
Oral bacteria
age-related microbiological changes, 5
selective medium for *B. gracilis*, 294
selective medium for formate-fumarate dependent bacterial, 294
Outer-membrane proteins (OMPs)
of *B. pertussis*, 185
of *H. influenzae*, 139
of *Y. enterocolitica*, 257

PACE 2, DNA probe assay, 152
Parainfluenza virus, 219
Penicillin resistance
of *S. aureus*, 72
of *X. maltophilia*, 208
Peptidoglycan, *B. pertussis* cell wall, 184
Periodontal disease, 294
Phagocytosis
E. coli by polymorphonuclear leucocytes, 12
S. epidermidis by monocytes, 65
S. epidermidis by polymorphonuclear leucocytes, 65
Pigs
"*Gastrospirillum suis*" in gastric mucosa, 345
Plaque
age-related changes in microflora, 5
formate-fumerate dependent isolates, 294
Plasmids
expression of proteins by *Y. enterocolitica*, 257
of multi-resistant *S. aureus*, 72
probes, in typing of *S. aureus*, 80
transfer, 72
virulence of *A. hydrophila*, 264
virulence of *E. coli*, 330
virulence of shigellae, 330
Polyethylene glycol precipitation, 291
Polymerase chain reaction (PCR), 1, 98, 188, 284
Polymorphonuclear leucocytes (PMNLs)
chemiluminescence, 65
phagocytosis and killing of *E. coli*, 12
phagocytosis of *S. epidermidis*, 65
role in intra-abdominal infection with *E. coli* and *B. fragilis*, 18
Polysaccharide, expression by *B. fragilis*, 229
PROCEEDINGS OF THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND, Vol. 35 No. 5 November 1991. pp i–ix
Protease
alkaline, of *A. fumigatus*, 23
P. mirabilis IgA protease, 203
Proteins
in *B. pertussis* infections, 185
in *B. pertussis* vaccines, 186
plasmid-mediated, of *Y. enterocolitica*, 257
polypeptide antigens of *B. fragilis*, 118
surface, of coagulase-negative staphylococci, 65
synthetic peptides, from *B. pertussis* toxin, 178
see also Outer-membrane proteins
Prystanamycin resistance, of *A. hydrophila*, 264
Pseudomonas aeruginosa
production of histidine decarboxylase, 363
Proteus mirabilis
dihydrofolate reductase, 214
IgA protease, 203
in urinary tract infections, 203
Pulmonary disease, chronic obstructive, 139
Pyelonephritis, mouse model, 324
Pyridoxal phosphate, 363
Pyrolysis mass spectrometry, 304

4-Quinolones
interactions with gyrase subunit B inhibitors, 358

Radiolabelling, of *H. pylori*, 197
Rat model
chronic lung infection by *H. influenzae*, 139
fibrin clot model, 18
intra-abdominal infection with *E. coli* and *B. fragilis*, 18
Respiratory syncytial virus, 219

Respiratory tract infections
acute viral, in children, 219
identification of *H. influenzae* in sputum, 49
chronic obstructive pulmonary disease, 139
histidine decarboxylase from isolates, 363
Restriction analysis
antigenic shifts in *C. coli* serostrains, 168
chromosomal DNA of group B β-haemolytic streptococci, 297
dihydrofolate reductase gene, 214
typing of *L. pneumophila*, 152
typing of *S. aureus*, 80
Restriction fragment length polymorphism typing, of *L. pneumophila*, 152
Rhamnose, fermentation by *E. coli*, 107
RNA, in ribotyping
of *L. pneumophila*, 152
of *M. leprae*, 284
Rosco system, 193

Salmonella typhimurium
antagonism by faecal bacteria, 111
invasion of HEp-2 cells, 349
passive secretory immune response, 53
role of nutrients in mixed culture, 111
virulence, 349
SDS-PAGE
analysis of *B. hominis* strains, 35
antigens of *B. fragilis*, 118
dihydrofolate reductase, 214
Septicaemia, 297
Serology
analysis of *B. hominis* strains, 35
concentration of hepatitis B virus from serum, 291
diagnosis by Chlamydia Spot-IF test, 244
diagnosis of toxoplasmosis, 1
Kemble Star 700 sample processor, 249
serodiagnosis of *B. fragilis*, 118
Serum, pre-opsonisation of *E. coli*, 12
Serratia marcescens
adherence to bladder epithelial cells, 93
pathogenesis in urinary tract infections, 93
Shadow casting, 338
Shigellae
contact-haemolysin production, 330
plasmids, 330
Siderophore
desferrioxamine, in identification of streptococci, 45
production by *E. coli* in urine, 324
role in *A. hydrophila* infection, 264
Sorbitol-MacConkey agar, 107
Spiral bacterium
"*Gastrospirillum suis*" in porcine gastric mucosa, 345
Spirochaetes
B. burgdorferi in cerebrospinal fluid, 98
in oral microflora, 5
Sputum samples
rapid identification of *H. influenzae*, 49
Staphylococci
coagulase-negative, susceptibility to desferrioxamine, 45
coagulase-negative, monoclonal antibodies, 65
in oral microflora, 5
S. aureus, methicillin-resistant, 80
S. aureus, multi-resistant, 72
S. aureus, plasmids, 72
S. aureus, transfer of resistance determinants, 72
S. aureus typing by DNA probes, 80
S. epidermidis, monoclonal antibodies, 65
S. epidermidis, surface proteins, 65
S. epidermidis, susceptibility to desferrioxamine, 45
Streptococci
analysis of chromosomal DNA, 297
group B β-haemolytic, 297
group G, biochemical properties, 148
group G, from cats, 148
monoclonal antibodies, 60
nephritis strain-associated streptokinase, 60
in oral microflora, 5
S. pyogenes, typing system, 304
viridans, biochemical identification scheme, 367
Streptokinase
nephritis strain-associated, 60
Streptomycin resistance, of *S. aureus*, 72
Sulphonamide plus pyrimethamine, 1
Superoxide anion-dependent fungicidal mechanism, 29

Tetanus toxoid potency potentiation by pertussis vaccine, 187
Tetracycline
resistance of *A. hydrophila*, 264
resistance of *S. aureus*, 72
susceptibility of mycoplasmas, 89
T-lymphocytes, in *B. pertussis* infection, 175
Tobramycin resistance, of *A. hydrophila*, 264
Toxins
of *C. difficile*, 40
pertussis, 175
see also Cytotoxins; Endotoxins; Enterotoxins
Toxoplasma gondii, detection of, 1
Toxoplasmosis
associated with AIDS, 1
clinical and diagnostic analysis, 1
treatment of, 1
Trimethoprim resistance, of *S. aureus*, 72

Ulcerative colitis, 238
Ultracentrifugation, 291
Urinary tract infections
S. marcescens, 93
E. coli, 324
P. mirabilis, 203
Urine
pre-opsonisation of *E. coli*, 12
siderophore production by *E. coli*, 324

Vaccines, against *B. pertussis*, 176
Vaginosis, bacterial, 103
Verotoxin, of *E. coli*, 107, 270
Virulence factors
A. fumigatus, 23
A. hydrophila, 264
B. fragilis, 229
B. pertussis, 174
E. coli, 270, 278, 324, 330
shigellae, 330
S. typhimurium, 349
Y. enterocolitica, 257

Western blotting, 35, 60
Whooping cough *see Bordetella pertussis*

Xanthomonas maltophilia
β-lactamase expression, 208
susceptibility to antibiotics, 208
X-ray spectrometry, 338

Yeasts, in oral microflora, 5
Yersinia enterocolitica
expression of plasmid-mediated proteins, 257

INDEX OF AUTHORS FOR VOLUME 35

ABUDU O O, *see* ROTIMI, *et al.*, 103
AGUILERA A, *see* BLANCO *et al.*, 162
AKOVA M, BONFIGLIO G, LIVERMORE D M. Susceptibility to β-lactam antibiotics of mutant strains of *Xanthomonas maltophilia* with high- and low level constitutive expression of L1 and L2 β-lactamases, 208
ALBERT M J, *see* HAIDER *et al.*, 330
ALKARMI T O, *see* ELHAG AND ALKARMI, 118
ALONSO M P, *see* BLANCO *et al.*, 162
AMIN I I, *see* DOUCE *et al.*, 349
AMPHLETT M, SMITH D J, WARREN R E. An assessment of the Kemble Star 700 sample processor for the automation of complement fixation and ELISA tests in a microbiology laboratory, 249
AUBERT SYLVIE, *see* MONZON-MORENO *et al.*, 80

BANJO T O, *see* ROTIMI *et al.*, 103
BARBOSA A J A, *see* MENDES *et al.*, 345
BARJA J L, *see* BORREGO *et al.*, 264
BEIGHTON D, HARDIE J M, WHILEY R A. A scheme for the identification of viridans streptococci, 367
BESNIER J M, *see* TIMMERMAN *et al.*, 65
BISHOP P A, *see* WADE *et al.*, 294
BLANCO J, GONZÁLEZ E A, BLANCO M, GARABAL J I, ALONSO M P, FERNÁNDEZ S, VILLANUEVA R, AGUILERA A, GARCIA M A, TORRES J, REY A, JANSEN W H, GUINÉE P A M. Enterotoxigenic *Escherichia coli* associated with infant diarrhoea in Galicia, north-western Spain, 162
BLANCO M, *see* BLANCO *et al.*, 162
BONFIGLIO G, *see* AKOVA *et al.*, 208
BORREGO J J, MORIÑIGO M A, MARTINEZ-MANZANARES E, BOSCA M, CASTRO DOLORES, BARJA J L, TORANZO ALICIA E. Plasmid associated virulence properties of environmental isolates of *Aeromonas hydrophila*, 264
BOSCA M, *see* BORREGO *et al.*, 264
BROWN M R W, *see* MACIVER *et al.*, 139
BRUMFITT W, *see* GARGAN *et al.*, 12
BRUMMER E, KURITA N, YOSHIDA S, NISHIMURA KAZUKO, MIYAJI M. Killing of *Histoplasma capsulatum by* γ-interferon-activated human monocyte-derived macrophages: evidence for a superoxide anion-dependent mechanism, 29

CARVALHO A C T, *see* MENDES *et al.*, 345
CASTRO DOLORES, *see* BORREGO *et al.*, 264
CHALLACOMBE S J, *see* PERCIVAL *et al.*, 5
CHAPMAN P A, SIDDONS CHRISTINE A, ZADIK P M, JEWES LINDA. An improved selective medium for the isolation of *Escherichia coli* O157, 107
CHATURVEDI U C, *see* JAIN *et al.*, 219
CHEASTY T, *see* SCOTLAND *et al.*, 278
COLSTON, M J, *see* COX *et al.*, 284
CORBEL M J, REDHEAD K. Recent developments in pertussis research, 174
CORBITT G, *see* SANYAL *et al.*, 291
COX R A, KEMPSELL K, FAIRCLOUGH L, COLSTON M J. The 16S ribosomal RNA of *Mycobacterium leprae* contains a unique sequence which can be used for identification by the polymerase chain reaction, 284
CROCKARD A D, *see* LUTTON *et al.*, 229
CUNDELL D R, DEVALIA J L, WILKS M, TABAQCHALI S, DAVIES R J. Histidine decarboxylase from bacteria that colonise the human respiratory tract, 363

DABIRSIAGHI CAROLYN L, *see* KRYWOLAP *et al.*, 338
DANKERT J, *see* STERK *et al.*, 129
DAVIES R J, *see* CUNDELL *et al.*, 363
DE GRAAF L, *see* TIMMERMAN *et al.*, 65
DEALLER S F, FOWERAKER JULIET, LAWSON PAPETA, FORTUNE SUSAN. Provisional identification of *Haemophilus influenzae* from sputum cultures within 1 h by rapid enzyme tests, 49
DERMOTT EVELYN, *see* LUTTON, *et al.*, 229
DEVALIA J L, *see* CUNDELL *et al.*, 363
DOUCE GILLIAN R, AMIN I I, STEPHEN J. Invasion of HEp2 cells by strains of *Salmonella typhimurium* of different virulence in relation to gastroenteritis, 349
DRUMM B, *see* HEMALATHA *et al.*, 197
DUERDEN B I, *see* GIAFFER *et al.*, 238

EL SOLH NÉVINE, *see* MONZON-MORENO *et al.*, 80
ELHAG K M, ALKARMI T O. A study of the antigenic composition of the fragilis group of *Bacteroides*, 118

FAIRCLOUGH L, *see* COX *et al.*, 284
FERNÁNDEZ S, *see* BLANCO *et al.*, 162
FISCHLSCHWEIGER W, *see* KRYWOLAP *et al.*, 338
FLEER A, *see* TIMMERMAN *et al.*, 65
FORTUNE SUSAN, *see* DEALLER *et al.*, 49
FOWERAKER JULIET, *see* DEALLER *et al.*, 49
FRENK E, *see* MONOD *et al.*, 23
FUJITA K, *see* NAGANO *et al.*, 297

GARABAL J I, *see* BLANCO *et al.*, 162
GARCIA M A, *see* BLANCO *et al.*, 162
GARGAN R A, BRUMFITT W, HAMILTON-MILLER J M T. Pre-opsonisation of *Escherichia coli* induces resistance to neutrophil killing in serum and urine: relationship to growth phase, 12
GARLAND SUZANNE M, *see* LEES *et al.*, 159
GARLAND SUZANNE M, *see* LESLIE AND GARLAND, 224
GEELEN-VAN DEN BROEK L, *see* STERK *et al.*, 129
GIAFFER M H, HOLDSWORTH C D, DUERDEN B I. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique, 238
GONZÁLEZ E A, *see* BLANCO *et al.*, 162
GRUBB W B, *see* UDO AND GRUBB, 72
GUINÉE P A M, *see* BLANCO *et al.*, 162
GUTHRIE R K, *see* REITMEYER *et al.*, 148

HAIDER KHALEDA, ALBERT M J, HOSSAIN A, NAHAR S. Contact-haemolysin production by entero-invasive *Escherichia coli* and shigellae, 330
HAMILTON-MILLER J M T, *see* GARGAN *et al.*, 12
HANSKI C, *see* NAUMANN *et al.*, 257
HARDIE J M, *see* BEIGHTON *et al.*, 367
HARJAI K, *see* SHARMA *et al.*, 324
HARRISON T G, *see* SAUNDERS *et al.*, 152
HASTINGS J G M, *see* LIMB *et al.*, 89
HATHTHOTUWA A, *see* SAUNDERS *et al.*, 152
HAWKEY P M, *see* KERR *et al.*, 193
HEMALATHA S G, DRUMM B, SHERMAN P. Adherence of *Helicobacter pylori* to human gastric epithelial cells *in vitro*, 197
HENNESSEY J N, *see* MILLS *et al.*, 168
HINDMARCH J M, *see* MAGEE *et al.*, 304

HOLDSWORTH C D, *see* GIAFFER *et al.*, 238
HOLLIMAN R E. Clinical and diagnostic findings in 20 patients with toxoplasmosis and the Acquired Immune Deficiency Syndrome, 1
HOPWOOD V, *see* MERSON-DAVIES *et al.*, 321
HOSSAIN A, *see* HAIDER *et al.*, 330
HOUTHOFF H J, *see* STERK *et al.*, 129
HOWARD B M A, *see* LEWIN *et al.*, 358

JAIN A, PANDE A, MISRA P K, MATHUR A, CHATURVEDI U C. An Indian hospital study of viral causes of acute respiratory infection in children, 219
JANSEN W H, *see* BLANCO *et al.*, 162
JEWES LINDA, *see* CHAPMAN *et al.*, 107
JOHNSTON K H, *see* OHKUNI *et al.*, 60

KATOULI M, KÜHN I, MÖLLBY R. Biochemical phenotypes of enteropathogenic *Escherichia coli* common to Iran and Sweden, 270
KEMPSELL K, *see* COX *et al.*, 284
KERR K G, ROTOWA N A, HAWKEY P M, LACEY R W. Evaluation of the Rosco system for the identification of *Listeria* species 193
KERR M A, *see* SENIOR *et al.*, 203
KOORNHOF H J, *see* WYLIE AND KOORNHOF, 214
KRÜGER W H, PULZ M. Detection of *Borrelia burgdorferi* in cerebrospinal fluid by the polymerase chain reaction, 98
KRYWOLAP G N, FISCHLSCHWEIGER W, DABIRSIAGHI CAROLYN L, MARGARET BARBARA S. Surface layers of *Eubacterium yurii* subsp. *yurii* and their possible role in test-tube brush formation and iron acquisition, 338
KUDESIA G, *see* SANYAL *et al.*, 291
KÜHN I, *see* KATOULI *et al.*, 270
KUKOSCHKE K G, MÜLLER H E. SDS-PAGE and immunological analysis of different axenic *Blastocystis hominis* strains, 35
KURITA N, *see* BRUMMER *et al.*, 29
KURJANCZYK L A, *see* MILLS *et al.*, 168

LACEY R W, *see* KERR *et al.*, 193
LAGE A P, *see* MENDES *et al.*, 345
LARKIN M J, *see* LUTTON *et al.*, 229
LAWSON PAPETA, *see* DEALLER *et al.*, 49
LEES M I, NEWNAN DIANE M, GARLAND SUZANNE M. Comparison of a DNA probe assay with culture for the detection of *Chlamydia trachomatis*, 159
LESLIE D E, GARLAND SUZANNE M. Comparison of immunofluorescence and culture for the detection of *Actinomyces israelii* in wearers of intra-uterine devices, 224
LEWIN C S, HOWARD B M A, SMITH J T. 4-Quinolone interactions with gyrase subunit B inhibitors, 358
LIMB D I, WHEAT P F, HASTINGS J G M, SPENCER R C. Antimicrobial susceptibility testing of mycoplasmas by ATP bioluminescence, 89
LINDSAY J A, RILEY T V. Susceptibility to desferrioxamine: a new test for the identification of *Staphylococcus epidermidis*, 45
LIVERMORE D M, *see* AKOVA, *et al.*, 208
LOOMES L M, *see* SENIOR *et al.*, 203
LUTTON DEBORAH A, PATRICK SHEILA, CROCKARD A D, STEWART LINDA D, LARKIN M J, DERMOTT EVELYN, MCNEILL T A. Flow cytometric analysis of within-strain variation in polysaccharide expression by *Bacteroides fragilis* by use of murine monoclonal antibodies, 229

MACIVER I, SILVERMAN S H, BROWN M R W, O'REILLY T. Rat model of chronic lung infections caused by non-typable *Haemophilus influenzae*, 139
MACLAREN D M, *see* VERWEIJ *et al.*, 18
MCNEILL T A, *see* LUTTON *et al.*, 229
MAGEE J T, HINDMARCH J M, NICOL C D. Typing of *Streptococcus pyogenes* by pyrolysis mass spectrometry, 304
MALLINSON H, *see* MANNION *et al.*, 244
MANNION P T, MALLINSON H, TREHARNE J D. Serological diagnosis with the Chlamydia Spot-IF test, 244
MARGARET BARBARA S, *see* KRYWOLAP *et al.*, 338
MAROT-LEBLOND A, *see* MERSON-DAVIES *et al.*, 321
MARSH P D, *see* PERCIVAL *et al.*, 5
MARTINEZ-MANZANARES E, *see* BORREGO *et al.*, 264
MATHUR A, *see* JAIN *et al.*, 219
MENDES E N, QUEIROZ DULCIENE M M, ROCHA G A, NOGUEIRA ANA M M F, CARVALHO A C T, LAGE A P, BARBOSA A J A. Histopathological study of porcine gastric mucosa with and without a spiral bacterium ("*Gastrospirillum suis*"), 345
MERSON-DAVIES L A, HOPWOOD V, ROBERT R, MAROT-LEBLOND A, SENET J-M, ODDS F C. Reaction of *Candida albicans* cells of different morphology index with monoclonal antibodies specific for the hyphal form, 321
MILLS S D, KURJANCZYK L A, SHAMES B, HENNESSY J N, PENNER J L. Antigenic shifts in serotype determinants of *Campylobacter coli* are accompanied by changes in the chromosomal DNA restriction endonuclease digestion pattern, 168.
MISRA P K, *see* JAIN *et al.*, 219
MITTAL R, *see* SHARMA *et al.*, 324
MIYAJI M, *see* BRUMMER *et al.*, 29
MÖLLBY R, *see* KATOULI *et al.*, 270
MONOD M, TOGNI G, RAHALISON L, FRENK E. Isolation and characterisation of an extracellular alkaline protease of *Aspergillus fumigatus*, 23
MONZON-MORENO C, AUBERT SYLVIE, MORVAN ANNE, EL SOLH NÉVINE. Usefulness of three probes in typing isolates of methicillin-resistant *Staphylococcus aureus* (MRSA), 80
MORIÑIGO M A, *see* BORREGO *et al.*, 264
MORVAN ANNE, *see* MONZON-MORENO *et al.*, 80
MÜLLER H E, *see* KUKOSCHKE AND MÜLLER, 35
MURONO K, *see* NAGANO *et al.*, 297

NAGANO N, *see* NAGANO *et al.*, 297
NAGANO YUKIKO, NAGANO N, TAKAHASHI S, MURONO K, FUJITA K, TAGUCHI F, OKUWAKI Y. Restriction endonuclease digest patterns of chromosomal DNA from group B β-haemolytic streptococci, 297
NAHAR S, *see* HAIDER *et al.*, 330
NAMAVAR F, *see* VERWEIJ *et al.*, 18
NAUMANN M, HANSKI C, RIECKEN E O. Expression *in vivo* of additional plasmid-mediated proteins during intestinal infection with *Yersinia enterocolitica* serotype O8, 257
NEWNAN DIANE M, *see* LEES *et al.*, 159
NICOL C D, *see* MAGEE *et al.*, 304
NISHIMURA KAZUKO, *see* BRUMMER *et al.*, 29
NISHINO T, *see* OBANA *et al.*, 93
NOGUEIRA ANA M M F, *see* MENDES *et al.*, 345

OBANA Y, SHIBATA K, NISHINO T. Adherence of *Serratia marcescens* in the pathogenesis of urinary tract infections in diabetic mice, 93

ODDS F C, *see* MERSON-DAVIES *et al.*, 321
OHKUNI H, TODOME YUKO, YOSHIMURA K, YAMAMOTO T, SUZUKI H, YOKOMURO K, JOHNSTON K H, ZABRISKIE J B. Detection of nephritis strain-associated streptokinase by monoclonal antibodies, 60
OKUWAKI Y, *see* NAGANO *et al.*, 297
O'REILLY T, *see* MACIVER *et al.*, 139

PANDE A, *see* JAIN *et al.*, 219
PENNER J L, *see* MILLS *et al.*, 168
PERCIVAL R S, CHALLACOMBE S J, MARSH P D. Age-related microbiological changes in the salivary and plaque microflora of healthy adults, 5
PULZ M, *see* KRÜGER AND PULZ, 98

QUEIROZ DULCIENE M M, *see* MENDES *et al.*, 345

RAHALISON L, *see* MONOD *et al.*, 23
REDHEAD K, *see* CORBEL AND REDHEAD, 174
REITMEYER J C, GUTHRIE R K, STEELE J H. Biochemical properties of group G streptococci isolated from cats and man, 148
REY A, *see* BLANCO *et al.*, 162
RIECKEN E O, *see* NAUMANN *et al.*, 257
REILY T V, *see* LINDSAY AND RILEY, 45
ROBERT R, *see* MERSON-DAVIES *et al.*, 321
ROCHA G A, *see* MENDES *et al.*, 345
ROTIMI V O, YAKUBU Z, ABUDU O O, BANJO T O. Direct Gram's stain of vaginal discharge as a means of diagnosing bacterial vaginosis, 103
ROTOWA N A, *see* KERR *et al.*, 193
ROWE B, *see* SCOTLAND *et al.*, 278

SAID B, *see* SCOTLAND *et al.*, 278
SANYAL D, KUDESIA G, CORBITT G. Comparison of ultracentrifugation and polyethylene glycol precipitation for concentration of hepatitis B virus (HBV) DNA for molecular hybridisation tests and the relationship of HBV-DNA to HBe antigen and anti-HBe status, 291
SAUNDERS N A, HARRISON T G, HATHTHOTUWA A, TAYLOR A G. A comparison of probes for restriction fragment length polymorphism (RFLP) typing of *Legionella pneumophila* serogroup 1 strains, 152
SCHIEMAN D A, *see* SHOPE AND SCHIEMANN, 53
SCHOUTEN W F, *see* VERWEIJ *et al.*, 18
SCOTLAND S M, SMITH H R, SAID B, WILLSHAW G A, CHEASTY T, ROWE B. Identification of enteropathogenic *Escherichia coli* isolated in Britain as enteroaggregative or as members of a subclass of attaching-and-effacing *E. coli* not hybridising with the EPEC adherence-factor probe, 278
SENET J-M, *see* MERSON-DAVIES *et al.*, 321
SENIOR B W, LOOMES L M, KERR M A. The production and activity *in vivo* of *Proteus mirabilis* IgA protease in infections of the urinary tract, 203
SETO A, *see* USHIJIMA AND SETO, 107
SHAMES B, *see* MILLS *et al.*, 168
SHARMA S, HARJAI K, MITTAL R. Enhanced siderophore production and mouse kidney pathogenicity in *Escherichia coli* grown in urine, 324
SHERMAN P, *see* HEMALATHA *et al.*, 197
SHIBATA K, *see* OBANA *et al.*, 93
SHOPE S R, SCHIEMANN D A. Passive secretory immunity against *Salmonella typhimurium* demonstrated with foster mouse pups, 53
SIDDONS CHRISTINE A, *see* CHAPMAN *et al.*, 107
SILVERMAN S H, *see* MACIVER *et al.*, 139
SLAYNE M A, *see* WADE *et al.*, 294
SMITH D J, *see* AMPHLETT *et al.*, 249
SMITH H R, *see* SCOTLAND *et al.*, 278
SMITH J T, *see* LEWIN *et al.*, 358
SPENCER R C, *see* LIMB *et al.*, 89
STEELE J H, *see* REITMEYER *et al.*, 148
STEPHEN J, *see* DOUCE *et al.*, 349
STERK L M T, VAN ALPHEN L, GEELEN-VAN DEN BROEK L, HOUTHOFF H J, DANKERT J. Differential binding of *Haemophilus influenzae* to human tissues by fimbriae, 129
STEWART LINDA D, *see* LUTTON *et al.*, 229
SUZUKI H, *see* OHKUNI *et al.*, 60

TABAQCHALI S, *see* CUNDELL *et al.*, 363
TAGUCHI F, *see* NAGANO *et al.*, 297
TAKAHASHI S, *see* NAGANO *et al.*, 297
TAYLOR A G, *see* SAUNDERS *et al.*, 152
TIMMERMAN C P, BESNIER J M, DE GRAAF L, TORENSMA R, VERKLEY A J, FLEER A, VERHOEF J. Characterisation and functional aspects of monoclonal antibodies specific for surface proteins of coagulase-negative staphylococci, 65
TODOME YUKO, *see* OHKUNI *et al.*, 60
TOGNI G, *see* MONOD *et al.*, 23
TORANZO ALICIA E, *see* BORREGO *et al.*, 264
TORENSMA R, *see* TIMMERMAN *et al.*, 65
TORRES J F. Purification and characterisation of toxin B from a strain of *Clostridium difficile* that does not produce toxin A, 40
TORRES J, *see* BLANCO *et al.*, 162
TREHARNE J D, *see* MANNION *et al.*, 244

UDO E E, GRUBB W B. Transfer of resistance determinants from a multi-resistant *Staphylococcus aureus* isolate, 72
USHIJIMA T, SETO A. Selected faecal bacteria and nutrients essential for antagonism of *Salmonella typhimurium* in anaerobic continuous flow cultures, 111

VAN ALPHEN L, *see* STERK *et al.*, 129
VERHOEF J, *see* TIMMERMAN *et al.*, 65
VERKLEY A J, *see* TIMMERMAN *et al.*, 65
VERWEIJ W R, NAMAVAR F, SCHOUTEN W F, MACLAREN D M. Early events after intra-abdominal infection with *Bacteroides fragilis* and *Escherichia coli*, 18
VILLANUEVA R, *see* BLANCO *et al.*, 162

WADE W G, BISHOP P A, SLAYNE M A. *Bacteroides ureolyticus* (NTU) medium for the selective recovery of *Bacteroides gracilis*, 294
WARREN R E, *see* AMPHLETT *et al.*, 249
WHEAT P F, *see* LIMB *et al.*, 89
WHILEY R A, *see* BEIGHTON *et al.*, 367
WILKS M, *see* CUNDELL *et al.*, 363
WILLSHAW G A, *see* SCOTLAND *et al.*, 278
WYLIE B A, KOORNHOF H J. Nucleotide sequence of dihydrofolate reductase type VI, 214

YAKUBU Z, *see* ROTIMI *et al.*, 103
YAMAMOTO T, *see* OHKUNI *et al.*, 60
YOKOMURO K, *see* OHKUNI *et al.*, 60
YOSHIDA S, *see* BRUMMER *et al.*, 29
YOSHIMURA K, *see* OHKUNI *et al.*, 60

ZABRISKIE J B, *see* OHKUNI *et al.*, 60
ZADIK P M, *see* CHAPMAN *et al.*, 107